Judy M. Luu

Judy M. Luu

Auto-generated profile, based on publicly available information

Judy M. Luu

Department of Medicine, McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2019 in European Heart Journal
Verified
Journal Article
Closed access
AHAchi Haider
Achi Haider
SBSusan Bengs
Susan Bengs
JLJudy Luu
Judy Luu
EOElena Osto
Elena Osto
JSJolanta M. Siller-Matula
Jolanta M. Siller-Matula
CGCatherine Gebhard
Catherine Gebhard
Although health disparities in women presenting with acute coronary syndrome (ACS) have received growing attention in recent years, clinical outcomes from ACS are still worse for women than for men. Women continue to experience higher patient and system delays and receive less aggressive invasive treatment and pharmacotherapies. Gender- and sex-specific variables that contribute to ACS vulnerability remain largely unknown. Notwithstanding the sex differences in baseline coronary anatomy and function, women and men are treated the same based on guidelines that were established from experimental and clinical trial data over-representing the male population. Importantly, younger women have a particularly unfavourable prognosis and a plethora of unanswered questions remains in this younger population. The present review summarizes contemporary evidence for gender and sex differences in vascular biology, clinical presentation, and outcomes of ACS. We further discuss potential mechanisms and non-traditional risk conditions modulating the course of disease in women and men, such as unrecognized psychosocial factors, sex-specific vascular and neural stress responses, and the potential impact of epigenetic modifications.

4 October 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JLJudy M. Luu
Judy M. Luu
JWJanet Wei
Janet Wei
CSChrisandra L. Shufelt
Chrisandra L. Shufelt
AAAnum Asif
Anum Asif
BTBenita Tjoe
Benita Tjoe
C. Noel Bairey MerzC. Noel Bairey Merz
C. Noel Bairey Merz
Background: Ischemia with no obstructive coronary artery disease is a condition associated with major adverse cardiovascular outcomes. To date, there are no specific American Heart Association or American College of Cardiology guidelines. The objective of this survey is to better understand the clinical practice and knowledge gaps that exist nationally. Methods and Results: Participant‐specific links for a survey with 11 questions and 3 reminders were sent between September and October 2020 to the American College of Cardiology CardioSurve Panel. The panel consist of randomly selected cardiologists (n=437) who represent the current profile of the American College of Cardiology US membership. The survey received a 30% response rate. Of the 172 respondents, 130 (76%) indicated that they have treated patients with ischemia with no obstructive coronary artery disease. Although the majority (69%) are generally confident in their ability to manage this condition, 1 of 3 report lack of confidence or are neutral. The American College of Cardiology/American Heart Association Chronic Stable Angina Guidelines are the most commonly used reference for treating ischemia with no obstructive coronary artery disease (81%), with most cardiologists wanting additional clinical guidance, such as randomized controlled trials (61%). More than 4 of 5 cardiologists rarely or never order advanced imaging modalities to assess coronary flow reserve. Approximately 2 of 3 of respondents frequently prescribe statins (68%), aspirin (66%), calcium channel blockers (63%), and β blockers or α/β blockers (55%). However, nearly 70% never prescribe angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers. Conclusions: This survey demonstrates heterogeneity in the management of ischemia with no obstructive coronary artery disease among US cardiologists, identifies support for guideline development, and outlines knowledge gaps for research and education in the therapeutic management of this condition.

31 March 2025 in Canadian Journal of Cardiology
Verified
Journal Article
Open access
MVMaya S. Verma
Maya S. Verma
KLKate Lindsay
Kate Lindsay
JNJiayi Ni
Jiayi Ni
MFMatthias G. Friedrich
Matthias G. Friedrich
JLJudy M. Luu
Judy M. Luu
Cardiovascular disease (CVD) is the leading cause of death in women, yet sex-specific risk factor influences remain understudied. Cardiac magnetic resonance imaging (CMR) detects early remodeling via left ventricular mass-to-volume ratio (LVMV), a validated concentricity marker. This study examines sex differences in the association of CV risk factors, diet, and cardiac remodeling. We analyzed 622 age-matched adults (51% female, mean age 50.8 ± 9.5) from the Courtois Cardiovascular Signature Program. LVMV was defined as LV systolic mass divided by end-diastolic volume. Alcohol and sugar intake was self-rated on a Likert scale. Mann-Whitney U and regression analyses assessed sex-specific associations between CV risk factors and LVMV. Hypertension was present in 20.6% of males and 17.4% of females; diabetes in 9.8% and 6.0%. Males had higher triglycerides, alcohol/sugar intake, and LVMV (0.92 ± 0.20 vs. 0.77 ± 0.18 g/ml). Hypertension correlated with higher LVMV in both sexes (males: ß=0.099, p<0.001; females: ß=0.078, p<0.05), while triglycerides (ß=0.032, p<0.05) and alcohol intake (H=19.41, p<0.0001) were male-specific predictors. In females, diabetes and sugar intake were significantly associated with LVMV (ß=0.102, ß=0.062, p<0.05). CV risk factors impact cardiac remodeling differently by sex. In males, LVMV was linked to triglycerides and alcohol intake, while in females, diabetes and sugar intake showed stronger associations. These results underscore the need for tailored cardiovascular prevention strategies that account for sex differences in metabolic and lifestyle risk factors.

26 March 2025 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
EEElias John Elenjickal
Elias John Elenjickal
CTChristoforos K. Travlos
Christoforos K. Travlos
JLJudy Luu
Judy Luu
SLSerge Lemay
Serge Lemay
RSRita S. Suri
Rita S. Suri
TMThomas A. Mavrakanas
Thomas A. Mavrakanas
Key Points: Treatment with sodium-glucose cotransporter-2 inhibitor (SGLT-2i) provides kidney and cardiovascular protection in patients with advanced CKD. The glycosuric action of SGLT-2i is attenuated in advanced CKD resulting in no change in glycated hemoglobin and fewer volume depletion events. The use of SGLT-2i did not increase the incidence of AKI, urine infections, fractures, or treatment discontinuation due to adverse events. Background: The efficacy and safety of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) in patients with advanced CKD, defined as an eGFR <30 ml/min per 1.73 m2, has not been adequately studied. Methods: We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials of SGLT-2i in adults. We searched the medical literature analysis and retrieval system online and excerpta medica database databases from inception to April 2024. The primary outcomes were composite kidney (worsening kidney function, kidney failure, and kidney or cardiovascular [CV] death) and CV (CV death or hospitalization for heart failure) outcomes. Secondary outcomes included other reported CV and kidney outcomes, eGFR slopes, mechanistic, and safety outcomes. The risk ratios (RR) were estimated using a random effects model. Interaction effects were estimated for treatment effect modification by baseline eGFR (<30 and ≥30 ml/min per 1.73 m2). Results: A total of ten randomized controlled trials were included (total of 4800 patients with eGFR <30 ml/min per 1.73 m2). Participants were randomized to receive either placebo or an SGLT-2i. The use of SGLT-2i was associated with a lower incidence of the primary composite kidney outcome in patients with eGFR <30 ml/min per 1.73 m2 (RR, 0.79; 95% confidence interval [CI], 0.70 to 0.89) and ≥30 ml/min per 1.73 m2 (RR, 0.71; 95% CI, 0.64 to 0.79). The incidence of the primary CV outcome was numerically lower in the SGLT-2i arm in patients with eGFR <30 ml/min per 1.73 m2 (RR, 0.88; 95% CI, 0.71 to 1.10). In patients with eGFR ≥30 ml/min per 1.73 m2, SGLT-2i use was associated with a lower incidence of the composite CV outcome (RR, 0.77; 95% CI, 0.71 to 0.83). However, there was no interaction between advanced CKD status and the effect of SGLT-2i on any of the primary or secondary outcomes. The incidence of adverse events was similar in both arms. Conclusions: SGLT-2i retain their kidney and CV protective effect in patients with advanced CKD, with no added safety concerns.

1 November 2025 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
MMMayssa Moukarzel
Mayssa Moukarzel
KSKian Soroush
Kian Soroush
YZYixing Zhang
Yixing Zhang
JGJean-Philippe Gouin
Jean-Philippe Gouin
MFMatthias G Friedrich
Matthias G Friedrich
JLJudy M. Luu
Judy M. Luu
BACKGROUND: Psychosocial stress is linked to the development of cardiovascular disease, with a more pronounced impact in female participants. This study investigates sex differences in the association between perceived stress and myocardial tissue characteristics, as assessed by cardiovascular magnetic resonance imaging, and evaluates the contribution of psychosocial burden, including caregiving and perceived social standing. METHODS: This study included 219 participants (53.9% females; mean age, 54.4±11.0 years) without overt cardiovascular disease, drawn from a prospective repository. Participants completed the perceived stress scale and cardiovascular magnetic resonance with native T1 and T2 mappings. Psychosocial variables included family caregiving responsibilities and perceived emotional support. The study investigated associations between perceived stress scale scores, and native T1 and T2 mapping sequences and assessed sex differences and psychosocial burden. RESULTS: High-stress female participants had significantly longer T1 times than low-stress female participants in both healthy and at-risk groups and longer T2 times in the at-risk group. No significant differences were observed in male participants. Perceived stress scale scores significantly predicted T1 values in female participants (95% CI, 0.088–3.517; P =0.040) but not in male participants (94% CI, −0.687 to 2.139; P =0.310). In multivariable analysis, caregiving burden and perceived emotional support were independent predictors of T1 in female participants ( P =0.009 and P =0.035, respectively) but not in male participants. CONCLUSIONS: Psychosocial stress was associated with early subclinical myocardial changes in female participants but not in male participants, suggesting sex-specific pathways linking stress to early myocardial remodeling. These findings support the integration of psychosocial factors into cardiovascular risk assessment for female individuals.

24 May 2025 in Biopsychosocial Science and Medicine
Verified
Journal Article
Closed access
YSYolanda Sánchez-Carro
Yolanda Sánchez-Carro
MMMayssa Msc Moukarzel
Mayssa Msc Moukarzel
MFMatthias G. Friedrich
Matthias G. Friedrich
JGJean-Philippe Gouin
Jean-Philippe Gouin
JLJudy M. Luu
Judy M. Luu
Objective: Beyond objective socioeconomic status (SES) indicators, subjective social status (SSS), an individual’s subjective perception of their social standing relative to others, has been independently linked to cardiovascular disease (CVD) morbidity and mortality. Some studies also report sex differences in the association between SSS and CVD. This study aimed to investigate these potential sex differences using advanced cardiac magnetic resonance imaging to detect subclinical CVD progression among healthy individuals. Methods: A cross-sectional study was conducted with 443 participants (mean age = 56.40, SD = 10.88; 52.14% females) free of CVD. All participants underwent cardiac magnetic resonance imaging for quantitative assessment of T1 and T2 mapping, reflecting respectively diffuse fibrosis and edema, as part of inflammatory processes in the heart. SSS was measured using the MacArthur Subjective Social Status Scale. Results: Female sex [b(SE) = 0.29 (0.10), p = .005], lower education [b(SE) = −0.23 (0.10), p = .026], and an interaction between sex and SSS [b(SE) = −0.15 (0.06), p = .019] were associated with higher T1 values, indicating a stronger association between lower SSS and cardiac fibrosis markers in females compared with males. No significant associations were found for T2 values. Conclusions: These findings extend the literature on the association of SSS with cardiovascular outcomes. Compared with males, females demonstrated a stronger association between lower SSS and an imaging marker of cardiac fibrosis among individuals free of CVD, further highlighting the relevance of sex-specific cardiovascular risk assessment.